Cancer
Therapeutic area
Oncology
Rare disease
No
- Definition
- A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Cancer
- Therapeutic area
- Oncology
- cancer
- CA
- cancer
- cell type cancer
- malignancy
- malignant growth
- malignant neoplasm
- malignant neoplasm (disease)
- malignant neoplastic disease
- malignant tumor
- malignant tumour
- neoplasm (disease), malignant
- neoplasm, malignant
- MT
- All therapeutic areas
- Oncology
- Severity
- Severe
- MONDO ID
- MONDO:0004992
- Parent condition
- MONDO:0005070
Related records
Broader conditions (6)
- Cancer or benign tumor
- Disease
- Disease by etiologic mechanism
- Human disease
- Neoplasm
- Neoplastic disease or syndrome
Narrower conditions (2,275)
- Acantholytic squamous cell skin carcinoma
- Acantholytic variant squamous cell breast carcinoma
- Acinar cell carcinoma
- Acinar lung adenocarcinoma
- Acinar prostate adenocarcinoma, foamy gland variant
- Acinar prostate adenocarcinoma, signet ring variant
- Acinar prostate mucinous adenocarcinoma
- Acinic cell breast carcinoma
- Acquired cystic disease-associated renal cell carcinoma
- Acquired polycythemia vera
- Acral lentiginous melanoma
- ACTH-producing pituitary gland carcinoma
- Acute basophilic leukemia
- Acute biphenotypic leukemia
- Acute erythroid leukemia
- Acute leukemia of ambiguous lineage
- Acute megakaryoblastic leukemia
- Acute megakaryoblastic leukemia in adult
- Acute megakaryoblastic leukemia in down syndrome
- Acute megakaryoblastic leukemia without down syndrome
Trials (201)
- "Principle Test" for Isolation and Characterization of Circulating Cancer Cells (CTC)-CXCR4+.
- 125I Seed Brachytherapy Combined With Immunotherapy for Primary, Recurrent, or Metastatic Malignant Tumors
- 5-Aminolevulinic Acid (5-ALA) Gliolan®: Usage Increase Proposal for Neurosurgical Procedures in High-Grade Gliomas
- 68Ga-TCR-FAPI PET/CT in Patients With Various Types of Cancer
- 99mTc-CNDG Injection in the Diagnosis of Malignant Tumors
- A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)
- A Clinical Study of the Safety and Tolerability of SHR-1901 in Subjects With Advanced Malignant Tumors
- A Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB3617 Capsule in Patients With Advanced Malignant Tumors
- A Clinical Trial Evaluating Injection of TQB6411 in Subjects With Advanced Malignant Tumors
- A Clinical Trial of TQB3909 Tablets in Subjects With Advanced Malignant Tumors
- A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors
- A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors
- A Clinical Trial to Evaluate Effect of IBB0979 in Patients With Advanced Malignant Tumors
- A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors
- A First-in-human Study of HRS2398 Tablets in Subjects With Advanced Malignant Tumors
- A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors
- A Multicenter "Ablate and Resect" Study of Novilase® Interstitial Laser Therapy for the Ablation of Small Breast Cancers
- A Phase 1 Study of SSGJ-709 in Patients With Advanced Malignant Tumors
- A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma
- A Phase I Clinical Study of HRS-7058 in Patients With Advanced Malignant Tumour
Approved drugs (177)
- Abemaciclib
- Abiraterone
- Acalabrutinib
- Aflibercept
- Aldesleukin
- Alectinib
- Allopurinol
- Alpelisib
- Anastrozole
- Apalutamide
- Aprepitant
- Arsenic trioxide
- Atezolizumab
- Avapritinib
- Avelumab
- Axitinib
- Azacitidine
- Belinostat
- Bendamustine
- Bevacizumab
Drugs in development (637)
- 4-demethyl-4-cholesteryloxycarbonylpenclomedine Phase 1
- 7-ethyl-10-hydroxycamptothecin Phase 1
- 9-aminocamptothecin Phase 1
- Abiraterone acetate Phase 1
- AC-480 Phase 1
- Acetaminophen Phase 3
- Acyclovir sodium Phase 3
- Adakitug Phase 1
- Adavosertib Phase 2
- Adebrelimab Phase 1
- Adenosine Phase 3
- AEE-788 Phase 1
- AEG-35156 Phase 1
- Afatinib Phase 3
- Afuresertib Phase 1
- Alemtuzumab Phase 2
- Alisertib Phase 1
- Alteplase Phase 2
- Altiratinib Phase 1
- Amantadine hydrochloride Phase 2
Other linked drugs (27)
- Adagrasib
- Amantadine
- Amifampridine
- Anamorelin hydrochloride
- Buprenorphine
- Copanlisib
- Copanlisib hydrochloride
- Dianhydrogalactitol
- Diclofenac sodium
- E-7090
- Epoetin theta
- Epoetin zeta
- Hydromorphone hydrochloride
- Methadone hydrochloride
- Metoclopramide
- Mifepristone
- Nelarabine
- Octreotide acetate
- Patritumab deruxtecan
- Rasburicase